• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MSB
Click for more information
6.45% $1.16

MESOBLAST LIMITED - Charts / Financials

Market Cap $1.318B  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

Mesoblast Limited is an Australia-based is developing a range of late-stage product... Mesoblast Limited is an Australia-based is developing a range of late-stage product candidates derived from its proprietary mesenchymal lineage cell therapy technology platforms. The Company’s Remestemcel-L is mesenchymal lineage stromal cell product platform and is in late-stage development for treatment of systemic inflammatory diseases, including Pediatric steroid refractory acute Graft versus Host Disease (SR-aGVHD), acute respiratory distress syndrome (ARDS) and Biologic refractory inflammatory bowel disease. Its Rexlemestrocel-L is mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of advanced chronic heart failure (CHF) and chronic low back pain (CLBP) due to degenerative disc disease. Two products are commercialized in Japan and Europe by the Company’s licensees, and it has a commercial partnership in Europe and China for certain Phase III assets.More

refresh Created with Sketch. REFRESH
Last update - 15.59pm 06/05/2024 (20 minute delay) ?
Day
Open $1.12   Day High $1.20   Day Low $1.11
Daily Volume 17944902
Bids   Sellers
Number Price Volume   Number Price Volume
5 $1.15 59978   3 $1.16 34019

Directors & Senior Management

Dr. Silviu Itescu Chief Executive Officer, Executive Director
Mr. William M. Burns Non-Executive Independent Vice Chairman of the Board
Mr. Andrew Chaponnel Interim Chief Financial Officer
Ms. Dagmar Rosa-Bjorkeson Chief Operating Officer
Mr. Peter Howard General Counsel, Corporate Executive
Dr. Eric A. Rose Executive Director, Chief Medical Officer
Mr. Justin Horst Head of Manufacturing
Mr. Michael Schuster Pharma Partnering
Ms. Geraldine Storton Head of Regulatory Affairs and Quality Management
Mr. Paul Hughes Joint Company Secretary
Mrs. Jane Bell Non-Executive Independent Chairman of the Board
Mr. Philip J. Facchina Non-Executive Independent Director
Mr. Philip R. Krause Non-Executive Independent Director
Mr. Joseph R. Swedish Non-Executive Independent Director

Data source: Refinitiv

(20min delay)
Last
$1.16 		Change
0.070(6.45%) 		Mkt cap ! $1.318B
Open High Low Value Volume
$1.12 $1.20 $1.11 $20.88M 17.94M

Buyers (Bids)

No. Vol. Price($)
5 59978 $1.15
 

Sellers (Offers)

Price($) Vol. No.
$1.16 34019 3
View Market Depth
Last trade - 16.10pm 06/05/2024 (20 minute delay) ?
Last
$1.15 		  Change
0.070 ( 5.63 %)
Open High Low Volume
$1.12 $1.20 $1.12 3733217
Last updated 15.59pm 06/05/2024 ?

Top Stories

Westpac tracks lower in profits in first half of 2024, with a 16% yoy drop amid slowing economy

Westpac Banking Corporation has reported a 16 percent drop in net profit (to $3.342 billion) for the first half of the 2024 financial year compared to the same time last year.
Mantle Minerals to kick off drilling at Mt Berghaus in WA Mantle Minerals (ASX:MTL) has announced it's kicking off a 122-hole drill run on-site its Mt Berghaus acreage in Western Australia.
Sold out signs go up for RIU Resources Roundup in Sydney More than 115 companies will be participating in this year's RIU Resources Roundup in Sydney.
Maiden drilling at West Arunta hints at major IOCG system for Rincon Rincon Resources believes that drill core picked up from a maiden program of work at its West Arunta project in Western Australia indicates potential for a major iron oxide copper gold deposit.
Tamboran is listing on the NYSE, and Wall Street is paying attention If you needed evidence that Tamboran Resources is bullish on the NT's Beetaloo Basin, look no further than its decision to list on the NYSE.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.